Akcea Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Beacon St, Boston, Massachusetts, 0210...Phone Number
(617) 207-0202Revenue
$119.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Akcea Therapeutics
Akcea Therapeutics, Inc. is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., the leader in RNA therapeutics. Akcea commercializes TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen), and with Ionis, is advancing a mature pipeline of novel medicines discovered by Ionis and based on Ionis proprietary antisense technology. TEGSEDI is approved in the U.S., E.U., Canada and Brazil, and WAYLIVRA is approved in the E.U.Explore more
Akcea Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Akcea Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Akcea Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Akcea Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Akcea Therapeutics has new funding data
Product Launch: Get notified when Akcea Therapeutics launches new products
Earning: See what the market has to say on Akcea Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Akcea Therapeutics
Check out if Akcea Therapeutics is spiking on competitors!
Check if Akcea Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Akcea Therapeutics
Find 2 more new buyers
Compare Similar Companies to Akcea Therapeutics
Compare insights from companies similar to Akcea Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Akcea Therapeutics
$119.9M
51-200
Private
$125M
2014
MF
Marc FinchAlignment & Operations Vice President, International
$827.1M
501-1,000
Public
$2.5B
1998
QN
Quintus NgumahVice President, Clinical Development & Chief Marketing Officer, Cos To The
$675.1M
1K - 5K
Private
$225M
2009
LM
Leslie MillingtonSenior Director, Business Strategy & Operations Chief of Staff
Company Profile Activity
Activity Insights
Akcea Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Akcea Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Akcea Therapeutics.
Akcea Therapeutics financials insights
Gather financial insights about Akcea Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Stock Offering
$125M
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Akcea Therapeutics is currently seeking a Associate Director, Global Project & Portfolio Management. (Carlsbad, CA)
Open Position
Akcea Therapeutics News & Media
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for Familial Chylomicronaemia Syndrome, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in Scotland
LONDON--(BUSINESS WIRE)--Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has enabled access to volanesorsen on the National Health Service (NHS) in Scotland for the treatment of familial chylomicronaemia syndrome (FCS).1 This decision will allow patients in Scotland with this rare and life-threatening condition to access the treatment through NHS Scotland. SMC’s acceptance follows recent apIonis et Akcea célèbrent la journée de sensibilisation au SCF avec les efforts de la communauté mondiale visant à célébrer les héros méconnus
BOSTON et CARLSBAD, Californie--(BUSINESS WIRE)--Ionis Pharmaceuticals (NASDAQ : IONS) et sa filiale à 100 %, Akcea Therapeutics, marquent aujourd’hui la 3e Journée de sensibilisation au syndrome de chylomicronémie familiale (SCF), une célébration mondiale organisée chaque année le premier vendredi de novembre pour accroître la sensibilisation aux défis associés à cette maladie débilitante et ultra rare. En collaboration avec les membres de la communauté SCF, Ionis et Akcea ont fait des progrèsIonis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes
BOSTON & CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia Syndrome (FCS) Awareness Day, a global observance held each year on the first Friday in November to build broader awareness of the challenges associated with this debilitating, ultra-rare disease. Together with members of the FCS community, Ionis and Akcea have made significant progress in efforts to help peIonis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Akcea Therapeutics
Sign Up For FreeTo access detailed company insights
Akcea Therapeutics, Inc. is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., the leader in RNA therapeutics. Akcea commercializes TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen), and with Ionis, is advancing a mature pipeline of novel medicines discovered by Ionis and based on Ionis proprietary antisense technology. TEGSEDI is approved i... Read More
